ABCSG 16/S.A.L.S.A. Summary
Prospective, randomized, open-label, multi-center, phase-II-study evaluating the effect of a secondary adjuvant endocrine therapy with anastrozole for 2 years vs. 5 years in patients with hormone-receptor-positive breast cancer after 5 years prior adjuvant endocrine therapy.
|Coordinating investigator:||Gnant, Michael; Vienna|
(Click to enlarge)